No registrations found.
ID
Source
Brief title
Health condition
healthy, young subjects
Sponsors and support
Intervention
Outcome measures
Primary outcome
skeletal muscle mass (quadriceps muscle cross sectional area (CSA))
Secondary outcome
maximal leg muscle strength (1RM), whole-leg muscle CSA, type I and II muscle fibre size, muscle protein synthesis rates, and muscle signalling and gene transcription responses
Background summary
Recovery from illness and/or injury often requires a period of physical inactivity. Short periods of inactivity disrupt muscle protein synthesis and breakdown rates, which lead to a loss of skeletal muscle mass. A loss of skeletal muscle mass has been shown to slow recovery and impact quality of life. It is therefore important to develop strategies that can prevent the loss of skeletal muscle mass during periods of inactivity.With the present study, we will investigate whether dietary supplementation with a protein hydrolysate can attenuate skeletal muscle loss following 7 days of one-legged knee immobilisation and augment the rate of muscle mass re-gain during recovery in young men.
Study objective
We hypothesize that protein hydrolysate supplementation will attenuate the loss in muscle mass during 7 days of immobilisation and will augment the rate of muscle mass re-gain during recovery.
Study design
1 week immobilisation, 2 weeks recovery
Intervention
Subjects will receive a nutritional supplement during immobilisation and recovery. This will be either a protein hydrolysate or a placebo
Inclusion criteria
1) Male
2) Aged 18-35 y
3) BMI 18.5-30.0 kg/m2
Exclusion criteria
1) (Family) history of thrombosis
2) (Family) history of Factor V Leiden, or other known thrombophilia (such as; protein C, protein S, antithrombin deficiency)
3) Lower limb, back or shoulder injuries (which may interfere with the use of crutches)
4) Allergies to milk protein
5) Lactose intolerance
6) Participation in structured resistance exercise program
7) All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g., arthritis, spasticity/rigidity, all neurological disorders and paralysis)
8) Any medications known to (or may) affect protein metabolism (i.e., corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
9) Diagnosed diabetes
10) Diagnosed metabolic, cardiovascular or intestinal disorders
11) A history of neuromuscular problems
12) Use of anti-coagulants
13) Use of protein and/or fish-oil supplements
14) Participation in a 2H2O study in the previous 6 months.
15) Smoking
16) Any recent hospital admission/ major surgery
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL7645 |
| Other | METC azM/UM : METC18-073 |